Anthony Jake Demetris

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi Distinguishing between recurrent primary sclerosing cholangitis and chronic rejection
    Anthony Jake Demetris
    Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15261, USA
    Liver Transpl 12:S68-72. 2006
  2. ncbi The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells
    Tong Wu
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Mol Cancer Ther 3:299-307. 2004

Collaborators

Detail Information

Publications2

  1. ncbi Distinguishing between recurrent primary sclerosing cholangitis and chronic rejection
    Anthony Jake Demetris
    Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15261, USA
    Liver Transpl 12:S68-72. 2006
    ..5. Potential discriminating features include liver size and gross appearance, and histopathology findings in the arterial tree, hilar lymph nodes, large and small bile ducts, interface zone, lobular, and perivenular regions...
  2. ncbi The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells
    Tong Wu
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Mol Cancer Ther 3:299-307. 2004
    ..These findings suggest that celecoxib inhibits cholangiocarcinoma growth partly through induction of apoptosis and inhibition of Akt phosphorylation...